CFTR and cystic fibrosis: Several studies are ongoing addressing the crucial role of novel modulator therapies in decreasing the long-term incidence/prevalence of chronic and recurrent airway infections, and it has been observed that certain CFTR modulators are capable of decreasing the prevalence of bacteria, particularly the key CF pathogen Pseudomonas aeruginosa (P. aeruginosa) in treated patients.